BofA lowered the firm’s price target on Sage Therapeutics to $24 from $25 and keeps a Neutral rating on the shares. The firm has updated its operating expense assumptions to reflect the expected annualized savings from the company’s strategic reorganization and also now assumes “a more conservative stance” in its estimates for Zurzuvae in PPD.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SAGE:
- Sage Therapeutics management to meet with Oppenheimer
- Sage Therapeutics price target lowered to $22 from $25 at RBC Capital
- Sage Therapeutics price target raised to $20 from $19 at Mizuho
- Sage Therapeutics price target lowered to $24 from $28 at TD Cowen
- Sage Therapeutics price target raised to $27 from $24 at Scotiabank
